{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:12:10Z","timestamp":1760242330926,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T00:00:00Z","timestamp":1493424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4\u20135 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment option for patients. This study investigated the impact of a combined treatment compared to treatment with histone deacetylase inhibitors. The experiments revealed that a treatment with histone deacetylase (HDAC) inhibitors could reduce cell viability to 59% for KMS 18 cell line and 46% for the U-266 cell line. The combined treatment led to a decrease of cell viability to 33% for KMS 18 and 27% for the U-266 cell line, thus showing a significantly better efficacy than the single treatment.<\/jats:p>","DOI":"10.3390\/ijms18050945","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T11:37:20Z","timestamp":1493725040000},"page":"945","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["CIK Cells and HDAC Inhibitors in Multiple Myeloma"],"prefix":"10.3390","volume":"18","author":[{"given":"David","family":"Stephan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn, Sigmund-Freud-Stra\u00dfe 25, 53105 Bonn, Germany"},{"name":"Hochschule Bonn-Rhein-Sieg, Von-Liebig-Stra\u00dfe 20, 53359 Rheinbach, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Weiher","sequence":"additional","affiliation":[{"name":"Hochschule Bonn-Rhein-Sieg, Von-Liebig-Stra\u00dfe 20, 53359 Rheinbach, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Schmidt-Wolf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn, Sigmund-Freud-Stra\u00dfe 25, 53105 Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,4,29]]},"reference":[{"key":"ref_1","first-page":"51","article-title":"Pomalidomide for the Treatment of Multiple Myeloma","volume":"5","author":"Clark","year":"2014","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00330-007-0738-3","article-title":"Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma","volume":"18","author":"Fenk","year":"2008","journal-title":"Eur. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Galson, D.L., Silbermann, R., and Roodman, G.D. (2012). Mechanisms of multiple myeloma bone disease. BoneKEy Rep., 1.","DOI":"10.1038\/bonekey.2012.135"},{"key":"ref_4","first-page":"1","article-title":"Immunological Dysregulation in Multiple Myeloma Microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e26663","DOI":"10.4161\/onci.26663","article-title":"Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma","volume":"2","author":"Soriani","year":"2013","journal-title":"OncoImmunology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Negrin","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_7","first-page":"1673","article-title":"Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells","volume":"21","author":"Lefterova","year":"1993","journal-title":"Exp. Hematol."},{"key":"ref_8","unstructured":"Guetgemann, S., Frank, S., Strehl, J., and Schmidt-Wolf, I.G. (2007). Cytokine-induced killer cells are type II natural killer T cells. GMS German Med.Sci., 5."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-010-0887-7","article-title":"Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)","volume":"137","author":"Hontscha","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Li, Y., and Mariuzza, R.A. (2014). Structural basis for recognition of cellular and viral ligands by NK cell receptors. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00123"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0969-2126(03)00047-9","article-title":"Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands","volume":"11","author":"McFarland","year":"2003","journal-title":"Structure"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mincheva-Nilsson, L., and Baranov, V. (2014). Cancer Exosomes and NKG2D Receptor\u2013Ligand Interactions: Impairing NKG2D-Mediated Cytotoxicity and Anti-Tumour Immune Surveillance, Elsevier. Seminars in Cancer Biology.","DOI":"10.1016\/j.semcancer.2014.02.010"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone Deacetylase Inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3892\/ijo.2014.2550","article-title":"Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells","volume":"45","author":"Goetze","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12032-014-0985-5","article-title":"Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience","volume":"31","author":"Bezecny","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the Treatment of Multiple Myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s00117-013-2625-z","article-title":"Klinik und Therapie des multiplen Myeloms","volume":"54","author":"Mai","year":"2014","journal-title":"Radiologe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e27414","DOI":"10.4161\/onci.27414","article-title":"The anticancer effects of HDAC inhibitors require the immune system","volume":"3","author":"West","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-015-0027-9","article-title":"The combination of dendritic cells-cytotoxic T lymphocytes\/cytokine-induced killer (DC-CTL\/CIK) therapy exerts immune and clinical responses in patients with malignant tumors","volume":"4","author":"Wang","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jcyt.2016.05.015","article-title":"Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell \/dendritic cell\u2013cytokine-induced killer cell therapy for treatment of gastric cancer in China: A systematic review and meta-analysis","volume":"18","author":"Mu","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Nwangwu, C.A., Weiher, H., and Schmidt-Wolf, I.G.H. (2016). Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma. Hematol. Oncol.","DOI":"10.1002\/hon.2326"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy","volume":"8","author":"Wu","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/5\/945\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:34:13Z","timestamp":1760207653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/5\/945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,29]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"alternative-id":["ijms18050945"],"URL":"https:\/\/doi.org\/10.3390\/ijms18050945","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2017,4,29]]}}}